MCID: PRS034
MIFTS: 48

Parasitic Helminthiasis Infectious Disease

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Parasitic Helminthiasis Infectious Disease

MalaCards integrated aliases for Parasitic Helminthiasis Infectious Disease:

Name: Parasitic Helminthiasis Infectious Disease 12 15
Helminthiasis 12 75 53 55 44 17 72
Intestinal Helminthiasis 53 72
Helminth Infection 12
Worm Infections 53
Worm Infection 12
Helminthosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:883
MeSH 44 D006373
NCIt 50 C84751
SNOMED-CT 68 27601005
UMLS 72 C0018889 C0348287

Summaries for Parasitic Helminthiasis Infectious Disease

Disease Ontology : 12 A parasitic infectious disease that occurs when part of the body is infested with parasitic worms such as cestodes, nematodes and trematodes.

MalaCards based summary : Parasitic Helminthiasis Infectious Disease, also known as helminthiasis, is related to angiostrongyliasis and enterobiasis. An important gene associated with Parasitic Helminthiasis Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are PAK Pathway and Allograft rejection. The drugs Praziquantel and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and skin, and related phenotype is digestive/alimentary.

Wikipedia : 75 Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals... more...

Related Diseases for Parasitic Helminthiasis Infectious Disease

Diseases related to Parasitic Helminthiasis Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 angiostrongyliasis 33.2 IL5 IL4 IL13
2 enterobiasis 33.1 IL5 IL4 IL13
3 paragonimiasis 33.0 RNASE3 MT-CO1 IL5 IL13
4 ascaridiasis 33.0 STH IL13 IL10
5 coenurosis 33.0 MT-ND1 MT-CO1
6 taeniasis 33.0 MT-ND1 MT-CO1 IL10
7 trichuriasis 33.0 STH IL13 IL10
8 ancylostomiasis 32.9 RNASE3 MT-CO1 EPGN
9 necatoriasis 32.9 IL5 IL10 EPGN
10 baylisascariasis 32.8 IL4 IL10
11 hymenolepiasis 32.6 STH MT-CO1
12 echinococcosis 32.4 MT-ND1 MT-CO1 IL5 IL10 CES1
13 schistosomiasis 32.3 RNASE3 IL5 IL4 IL13 IL10 CD40LG
14 trichinosis 32.3 IL5 IL4
15 cytokine deficiency 31.8 IL5 IL13
16 hypereosinophilic syndrome 31.7 RNASE3 IL5 IL4 IL13
17 onchocerciasis 31.6 RNASE3 IL5 IL4 IL13
18 loiasis 31.3 SRCIN1 IL10
19 ige responsiveness, atopic 31.3 RNASE3 IL5 IL4 IL13 IL10
20 parasitic protozoa infectious disease 31.1 MT-CO1 IL4 IL10
21 urinary schistosomiasis 31.0 RNASE3 IL5 IL4 IL13
22 rhinitis 31.0 RNASE3 IL5 IL4 IL13
23 dermatitis, atopic 30.9 RNASE3 IL5 IL4 IL13 IL10
24 endomyocardial fibrosis 30.9 IL4 IL10
25 pulmonary eosinophilia 30.8 RNASE3 IL5 IL4 IL13
26 allergic asthma 30.8 RNASE3 IL5 IL4 IL13 IL10
27 elephantiasis 30.8 SRCIN1 RNASE3 GPT2
28 allergic hypersensitivity disease 30.7 RNASE3 IL5 IL4 IL13 IL10
29 gastroenteritis 30.7 RNASE3 IL5 IL4 IL10
30 keratoconjunctivitis 30.7 RNASE3 IL5 IL4 IL13
31 filarial elephantiasis 30.7 STH SRCIN1 IL5 IL4 IL10 GPT2
32 rubella 30.7 IL4 IL10 CD40LG
33 conjunctivitis 30.6 RNASE3 IL5 IL4 IL13
34 toxoplasmosis 30.6 IL4 IL10 CD40LG
35 malaria 30.6 MT-CO1 IL5 IL4 IL13 IL10 CD40LG
36 tetanus 30.6 IL5 IL4 IL13 IL10 CD40LG
37 intestinal schistosomiasis 30.6 SRCIN1 SNAI1 IL5 IL4 IL13 CHRM2
38 otitis media 30.5 RNASE3 IL4 IL10
39 cutaneous leishmaniasis 30.5 IL5 IL4 IL13 IL10
40 allergic rhinitis 30.5 RNASE3 IL5 IL4 IL13 IL10
41 leishmaniasis 30.5 IL5 IL4 IL13 IL10
42 skin disease 30.5 RNASE3 IL5 IL4 IL13 IL10
43 immune system disease 30.4 IL5 IL4 IL10
44 immune deficiency disease 30.3 IL4 IL13 IL10 CD40LG
45 pneumonia 30.3 IL5 IL13 IL10 CD40LG
46 respiratory allergy 30.3 RNASE3 IL5 IL4 IL13 IL10
47 upper respiratory tract disease 30.3 RNASE3 IL5 IL4 IL13 IL10
48 food allergy 30.3 RNASE3 IL5 IL4 IL13 IL10
49 bronchiolitis 30.3 RNASE3 IL5 IL4 IL13 IL10
50 cystic echinococcosis 30.3 MT-ND1 MT-CO1 IL10 CES1

Graphical network of the top 20 diseases related to Parasitic Helminthiasis Infectious Disease:



Diseases related to Parasitic Helminthiasis Infectious Disease

Symptoms & Phenotypes for Parasitic Helminthiasis Infectious Disease

MGI Mouse Phenotypes related to Parasitic Helminthiasis Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.17 CD4 IL10 IL13 IL4 IL5 SNAI1

Drugs & Therapeutics for Parasitic Helminthiasis Infectious Disease

Drugs for Parasitic Helminthiasis Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Artemether Approved Phase 4 71963-77-4 68911 119380
4
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
7
leucovorin Approved Phase 4 58-05-9 143 6006
8
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
9
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
10
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
11
Zinc Approved, Investigational Phase 4 7440-66-6 32051
12
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
15
Copper Approved, Investigational Phase 4 7440-50-8 27099
16
Iodine Approved, Investigational Phase 4 7553-56-2 807
17
Ferrous fumarate Approved Phase 4 141-01-5
18
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
19
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
24
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
25
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
26
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
27
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
29
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
30
Cobalamin Experimental Phase 4 13408-78-1 6857388
31 Tocotrienol Investigational Phase 4 6829-55-6
32 Artemether, Lumefantrine Drug Combination Phase 4
33 Vaccines Phase 4
34 Citrate Phase 4
35 DMP 777 Phase 4 157341-41-8
36 Piperazine citrate Phase 4
37 Micronutrients Phase 4
38 Trace Elements Phase 4
39 Antioxidants Phase 4
40 Vitamins Phase 4
41 Protective Agents Phase 4
42 Nutrients Phase 4
43 Folate Phase 4
44 Vitamin B9 Phase 4
45 Vitamin B 12 Phase 4
46 Vitamin B Complex Phase 4
47 Vitamin B12 Phase 4
48 retinol Phase 4
49 Retinol palmitate Phase 4
50 Lipoxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Intestinal Microbiome Post-Azythromycin/Albendazole Treatment Unknown status NCT03032042 Phase 4 Azithromycin;Albendazole;Delayed treatment
2 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
3 Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population Completed NCT02385058 Phase 4 Mebendazole;Quinfamide;Placebo
4 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
5 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
6 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
7 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
8 The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya Completed NCT02397772 Phase 4 albendazole
9 Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project Completed NCT01088958 Phase 4
10 Chengdu Women's and Children's Central Hospital Completed NCT02675140 Phase 4 ZENTEL;ZENTEL and Vitamin A Soft Capsules
11 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
12 A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam Withdrawn NCT02597556 Phase 4 Albendazole;Placebo
13 An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive Completed NCT01173562 Phase 3 Mebendazole
14 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
15 To Assess the Effectiveness of Six-Monthly Deworming With Vitamin A Administration on Growth in 1-5 Year Old Children in the Urban Slums of Lucknow Completed NCT00396500 Phase 3 Albendazole (400 mg) and/or Vitamin a
16 A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects Completed NCT02034162 Phase 3 Mebendazole;Placebo
17 Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections Completed NCT01350271 Phase 3 Mebendazole polymorph A and C 500 mg;Mebendazole polymorph C;Placebo
18 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
19 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
20 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
21 A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
22 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
23 Efficacy and Safety of Ascending Dosages of Albendazole Against T. Trichiura and Hookworm in Preschool- and School-aged Children and Adults: a Randomized Controlled Trial Recruiting NCT03527745 Phase 2 Albendazole;Albendazole;Albendazole;Albendazole;Placebo
24 Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis Active, not recruiting NCT03441893 Phase 1, Phase 2 Nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet;Mesalazine 250Mg
25 Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients Not yet recruiting NCT04041453 Phase 2 Ivermectin;Albendazole
26 An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults Withdrawn NCT02636803 Phase 2 oxfendazole;albendazole
27 The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren Completed NCT01640626 Phase 1
28 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
29 Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers. Completed NCT03192449 Phase 1 Albendazole.
30 A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males Completed NCT01755637 Phase 1 Albendazole
31 Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults Completed NCT02126462 Phase 1
32 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
33 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
34 Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel, With or Without a CpG ODN Adjuvant, in Healthy Adults Completed NCT02143518 Phase 1
35 Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® in Healthy Adults Completed NCT01717950 Phase 1
36 Phase I Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With Different Doses of the Novel Immunostimulant GLA-AF in Healthy Adults Completed NCT01385189 Phase 1
37 Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil) Completed NCT03173742 Phase 1 T1, T2, T3;T1,T3,T2;T2,T1,T3;T2,T3,T1;T3,T1,T2;T3,T2,T1
38 Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With or Without GLA-AF in Brazilian Adults Completed NCT01261130 Phase 1
39 A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers Completed NCT03035760 Phase 1 Oxfendazole
40 Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Na-GST-1/Alhydrogel®, With or Without a CPG ODN Adjuvant, in Gabonese Adults Active, not recruiting NCT03373214 Phase 1
41 Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants Unknown status NCT02714348
42 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
43 Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area Unknown status NCT01308268 Ivermectin + Albendazole
44 The Effectiveness of Multiple Micronutrient Supplements Given by Teachers to School-Age Children on Growth and Educational Achievement Unknown status NCT00859911
45 Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual Completed NCT02399683
46 Mucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected Individual Completed NCT03079700
47 Epidemiology of H. Pylori Transmission and Immunoepidemiology of Concomitant Infections Completed NCT02740140
48 The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis Completed NCT00857116 Albendazole;Placebo
49 Immunological Consequences of Helminth and Mycobacterial Coinfection Completed NCT00342017
50 Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding. Completed NCT00130910 Albendazole;Placebo

Search NIH Clinical Center for Parasitic Helminthiasis Infectious Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Albendazole
Antihelminthic [EPC]
Mebendazole
Niclosamide
Oxamniquine
Praziquantel
Thiabendazole

Cochrane evidence based reviews: helminthiasis

Genetic Tests for Parasitic Helminthiasis Infectious Disease

Anatomical Context for Parasitic Helminthiasis Infectious Disease

MalaCards organs/tissues related to Parasitic Helminthiasis Infectious Disease:

41
Testes, Liver, Skin, Breast, Heart, Bone, Whole Blood

Publications for Parasitic Helminthiasis Infectious Disease

Articles related to Parasitic Helminthiasis Infectious Disease:

(show top 50) (show all 1519)
# Title Authors PMID Year
1
[Toxocariasis in children--difficult clinical problem]. 9 38
18807488 2008
2
Recent advances in the characterization of genetic factors involved in human susceptibility to infection by schistosomiasis. 9 38
19471606 2008
3
Eosinophil cationic protein as a possible marker of active human Toxocara infection. 9 38
11703226 2001
4
Hyperimmunoglobulinemia E in the absence of atopy and filarial infection: the Huaorani of Ecuador. 9 38
11191097 2000
5
Inverse association between skin response to aeroallergens and Schistosoma mansoni infection. 9 38
11060486 2000
6
Possible relationship between allergic disease and infection by Giardia lamblia. 9 38
8452315 1993
7
Soil-transmitted helminthiases in Nepal: Transmission boundaries and implications for local communities and international travelers. 38
30991017 2019
8
Gaps and barriers in interventions for the control of soil-transmitted helminthiasis among school-age children in an endemic area of the Philippines: a school-based point-of-view. 38
31391522 2019
9
Efficacy and Safety of Ascending Dosages of Tribendimidine Against Hookworm Infections in Children: A Randomized Controlled Trial. 38
30496350 2019
10
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 38
31402376 2019
11
Anti-Ascaris suum immunoglobulin Y as a novel biotechnological tool for the diagnosis of human ascariasis. 38
31409433 2019
12
Therapeutic efficacy of albendazole against soil-transmitted helminthiasis in children measured by five diagnostic methods. 38
31369562 2019
13
Challenges in the control of soil-transmitted helminthiasis in Sichuan, Western China. 38
31404523 2019
14
Prevalence and risk factors of soil-transmitted helminthiasis among school children living in an agricultural area of North Sumatera, Indonesia. 38
31391023 2019
15
Soil-Transmitted Helminthiasis in Children from a Rural Community Taking Part in a Periodic Deworming Program in the Peruvian Amazon. 38
31309921 2019
16
Helminthiasis among School-Age Children and Hygiene Conditions of Selected Schools in Lafia, Nasarawa State, Nigeria. 38
31362367 2019
17
Assessing competence for helminthiases: A lesson learnt from national contest of parasitic diseases in China in 2012-2016. 38
31299284 2019
18
Integrated community-based intervention for urinary schistosomiasis and soil-transmitted helminthiasis in children from Caxito, Angola. 38
31290969 2019
19
Child development center-based sentinel surveillance of soil-transmitted helminthiases in preschool-age children in selected local government units in the Philippines. 38
30914241 2019
20
Ascariasis as a model to study the helminth/allergy relationships. 38
30295330 2019
21
Evaluation of the schistosomicidal, antioxidant and anti-inflammatory activities of the ethyl acetate fraction from Ozoroa pulcherrima Schweinf. Roots on Schistosoma mansoni-induced liver pathology in mice and its phytochemical characterization. 38
30999012 2019
22
Morbidity Associated with Chronic Strongyloides stercoralis Infection: A Systematic Review and Meta-Analysis. 38
30963990 2019
23
Pattern and determinants of soil-transmitted helminthiasis in a rural area of Haryana: A school-based study. 38
31334164 2019
24
Provision of deworming intervention to pregnant women by antenatal services in countries endemic for soil-transmitted helminthiasis. 38
31083673 2019
25
Characterization of a non-sexual population of Strongyloides stercoralis with hybrid 18S rDNA haplotypes in Guangxi, Southern China. 38
31059500 2019
26
Multimicronutrient Biomarkers Are Related to Anemia during Infancy in Indonesia: A Repeated Cross-Sectional Study. 38
31037278 2019
27
Associations between soil-transmitted helminthiasis and viral, bacterial, and protozoal enteroinfections: a cross-sectional study in rural Laos. 38
31064387 2019
28
Small bowel obstruction complicating an Ascaris lumbricoides infestation in a 4-year-old male: a case report. 38
31122293 2019
29
Analysis of Schistosomiasis and soil-transmitted helminths mixed infections among pupils in Enugu State, Nigeria: Implications for control. 38
30648601 2019
30
In vitro anthelmintic effects of Bridelia ferruginea, Combretum glutinosum, and Mitragyna inermis leaf extracts on Haemonchus contortus, an abomasal nematode of small ruminants. 38
30848351 2019
31
Prevalence of gastrointestinal helminths and parasites in smallholder pigs reared in the central Free State Province. 38
31038321 2019
32
Epidemiological Survey on Schistosomiasis and Intestinal Helminthiasis among Village Residents of the Rural River Basin Area in White Nile State, Sudan. 38
31104405 2019
33
Efficacy of Albendazole and Mebendazole With or Without Levamisole for Ascariasis and Trichuriasis. 38
31110573 2019
34
Chamomile Methanolic Extract Mitigates Small Bowel Inflammation and ROS Overload Related to the Intestinal Nematodes Infection in Mice. 38
30671769 2019
35
Cytotoxic and apoptotic inducing activity of Amoora rohituka leaf extracts in human breast cancer cells. 38
30846274 2019
36
[STRUCTURAL, MOLECULAR AND FUNCTIONAL FEATURES OF THE TREMATODE TEGUMENT AND OF ANTHELMINTIC DRUGS DEVELOPMENT (REVIEW)]. 38
31101791 2019
37
Bioassay-guided isolation of anti-seizure principles from Semen Pharbitidis using a zebrafish pentylenetetrazol seizure model. 38
30572093 2019
38
Detection of helminths by loop-mediated isothermal amplification assay: a review of updated technology and future outlook. 38
30905322 2019
39
Androgen-dependent immune modulation in parasitic infection. 38
30353258 2019
40
A retrospective administrative database analysis of the association between clonorchiasis or helminthiasis and the development of cholelithiasis. 38
30071748 2019
41
Assessment of health education products aimed at controlling and preventing helminthiases in China. 38
30909961 2019
42
Efficacy and safety of ivermectin and albendazole co-administration in school-aged children and adults infected with Trichuris trichiura: study protocol for a multi-country randomized controlled double-blind trial. 38
30885157 2019
43
Infectious diseases at different stages of migration: an expert review. 38
30726941 2019
44
Oral nitazoxanide treatment of experimental neurocysticercosis induces gluconeogenesis in Taenia crassiceps cysticerci. 38
30553893 2019
45
Persistent eosinophilia in rheumatoid arthritis: a prospective observational study. 38
30426234 2019
46
Odds, challenges and new approaches in the control of helminthiasis, an Asian study. 38
30662968 2019
47
Social media and control of soil-transmitted helminthiasis in Bhutan. 38
30817763 2019
48
Epidemiological and clinical profile of intestinal parasitosis of children in rural areas in Central African Republic. 38
30554848 2019
49
Gastrointestinal helminths of backyard chickens in selected areas of West Shoa Zone Central, Ethiopia. 38
30929942 2019
50
Helminthiasis Epidemiology and Control: Scoring Successes and Meeting the Remaining Challenges. 38
30878055 2019

Variations for Parasitic Helminthiasis Infectious Disease

Expression for Parasitic Helminthiasis Infectious Disease

Search GEO for disease gene expression data for Parasitic Helminthiasis Infectious Disease.

Pathways for Parasitic Helminthiasis Infectious Disease

Pathways related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 TXNRD3 SNAI1 IL5 IL4 IL13 IL10
2
Show member pathways
12.66 RNASE3 IL5 IL4 IL13 IL10 ICOSLG
3
Show member pathways
12.52 IL4 IL10 ICOSLG CD40LG CD4
4
Show member pathways
12.46 IL5 IL4 IL13 IL10 CD4
5
Show member pathways
12.4 IL5 IL4 IL10 CD40LG CD4
6
Show member pathways
12.28 IL5 IL4 IL13 IL10
7
Show member pathways
11.95 IL5 IL4 IL13 IL10 CD4
8 11.86 IL4 IL13 IL10
9 11.84 IL5 IL4 IL10 CD4
10 11.77 IL5 IL4 CD4
11 11.69 IL5 IL4 IL13
12
Show member pathways
11.65 IL5 IL4 CD40LG
13 11.61 IL4 IL13 IL10
14 11.55 IL5 IL4 IL13
15 11.47 IL5 IL4 IL10 CD40LG
16 11.46 IL10 CD40LG CD4
17 11.46 IL5 IL4 IL13 IL10 CD4
18 11.41 IL4 IL13 IL10
19 11.2 IL5 IL4 CD40LG
20 11.18 IL5 IL4 IL13
21 11.03 IL5 IL4 IL13 IL10 CD40LG
22 11.02 IL5 IL4 IL13 IL10 CD4
23 10.97 IL5 IL4 IL13 IL10
24 10.91 IL5 IL4 IL13 IL10 CD40LG
25 10.48 IL5 IL4 IL13 IL10 CD4

GO Terms for Parasitic Helminthiasis Infectious Disease

Cellular components related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 SERPINA3 RNASE3 IL5 IL4 IL13 IL10

Biological processes related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 SNAI1 IL5 IL4 IL10 CD4
2 inflammatory response GO:0006954 9.85 SERPINA3 IL5 IL13 IL10 CD40LG
3 B cell differentiation GO:0030183 9.69 IL4 IL10 CD40LG
4 positive regulation of T cell proliferation GO:0042102 9.67 IL4 CD40LG CD4
5 T cell activation GO:0042110 9.61 IL4 ICOSLG CD4
6 positive regulation of macrophage activation GO:0043032 9.52 IL13 IL10
7 positive regulation of B cell proliferation GO:0030890 9.5 IL5 IL4 IL13
8 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL4 IL10
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.43 IL4 IL13 IL10
10 type 2 immune response GO:0042092 9.4 IL4 IL10
11 regulation of isotype switching GO:0045191 9.37 IL4 IL10
12 cytokine-mediated signaling pathway GO:0019221 9.35 IL5 IL4 IL13 IL10 CD4
13 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL4 IL13
14 immune response GO:0006955 9.1 IL5 IL4 IL13 IL10 CD40LG CD4

Molecular functions related to Parasitic Helminthiasis Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL5 IL4 IL10 EPGN
2 cytokine activity GO:0005125 9.02 IL5 IL4 IL13 IL10 CD40LG

Sources for Parasitic Helminthiasis Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....